Mass General Brigham has revealed the development of an AI company and also a screening tool, which has sped up the process to determine eligibility and enrollment of patients for clinical trials.
AIwithCare is a spinout of Mass General Brigham and is founded by the researchers from the health system. RECTIFIER, the AIwithCare’s AI tool, which stands for RAG-Enabled Clinical Trial Infrastructure for Inclusion Exclusion Review, goes on to determine the eligibility of patients when it comes to clinical trials. It was initially developed by the researchers at the academic research group Accelerator for Clinical Transformation at Mass General Brigham.
RECTIFIER from AIwithCare makes use of generative AI to screen an electronic health record of a patient for information that can actually determine the eligibility for a clinical trial, like diagnoses, key health indicators, and also present or past medications. The tool also goes on to evaluate the unstructured data, which is available in notes as well as reports. These are often critical for determining the trial eligibility; however, they are typically inaccessible without having a time-consuming manual review process in place.
Interestingly, it also saves on the cost when it comes to determining the eligibility and also the enrollment for clinical trials.
Mass General Brigham opines that fast, accurate, and cost-effective medical analytics can alter the way medical data can get used for patients, providers, and health systems.
RECTIFIER from AIwithCare has resulted in over 20 active as well as onboarding use cases when it comes to research and clinical operations, including within the gamut of cardiology, gastroenterology, neurology, oncology, pathology, and psychiatry.
Its use continues to widen throughout the health system and will be expanded to other providers, confirmed Mass General Brigham. Researchers plan to scale this capacity to other healthcare systems and hospitals as well as clinics that are looking to match their patient populations along with clinical trials that are relevant.
In addition to this, Mass General Brigham is also making use of RECTIFIER so as to speed up the patient identification and also decrease the burden of manual chart review within the clinical as well as population health use cases.
RECTIFIER is getting used by pediatric gastroenterologists in order to perform patient referral triage and demonstrating 94.7% precision. In identifying the urgent labs and symptoms buried within the clinical notes, it has demonstrated an accuracy of 98%.
The Mass General Brigham Population Health Service Organization is making use of RECTIFIER in order to streamline the patient eligibility for a heart failure management program. There are other groups that are using RECTIFIER so as to perform high-resolution phenotyping of patients having sickle cell disease or across the ALS trials in order to speed up the patient identification for life-altering therapeutics.
It is well to be noted that RECTIFIER is the first AI tool by Mass General Brigham that involves a Retrieval-Augmented Generation – RAG AI application, which has been developed by the researchers within the health system.
One of the 2024 NEJM AI studies found out that RECTIFIER more precisely went and identified eligible patients for clinical trials as compared to manual screening, and that too at less cost vis-à-vis traditional methods.
Apparently, a follow-up randomized trial of almost 4,500 patients that was published in JAMA in 2025 found out that the rate of eligibility along with enrollment was almost double that of the traditional manual screening.
There were no prominent differences within the trial eligibility and enrollment rates in separate evaluations factoring in race, gender, and ethnicity of the patients, said the study.
Mass General Brigham Innovation has gone on to facilitate the new company spinout.
The innovation arm goes ahead and works along with the researchers in order to manage the tech transfer commercialization and also coordinate the industrial relationships, like the formation of new companies, licensing agreements, and other contracts, besides the intellectual property – IP management along with general advising.
In 2025, Mass General Brigham Innovation had over 1,400 active licenses, more than 600 new inventions disclosed, and almost 200 issued U.S. patents.
Chief Innovation Officer at Mass General Brigham, Chris Coburn, says that advancing AI, which can streamline matching patients along with clinical trials, goes on to reflect their commitment to practical innovation, which strengthens patient care and also expands access to certain promising therapies. He adds that such technology more broadly could enable the reduction of major barriers in terms of care delivery and in the end would accelerate the clinical research.